Lack of effect of cholestyramine on phenytoin bioavailability.
The effect of cholestyramine (4 g qid for 5 days) on the kinetics of phenytoin (400 mg orally) was investigated in normal subjects. Apart from a trend toward faster phenytoin absorption, the serum level profile of the drug during concurrent cholestyramine coadministration was similar to that observed in a control session. Areas under the serum phenytoin concentration curves were virtually identical in the two occasions. It is concluded that cholestyramine does not significantly affect the bioavailability of a single dose of phenytoin.
Barzaghi
N
N
Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Monteleone
M
M
Amione
C
C
Lecchini
S
S
Perucca
E
E
Frigo
G M
GM
D000328:Adult; D001682:Biological Availability; D002792:Cholestyramine Resin / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D008297:Male; D010672:Phenytoin / Q000493:pharmacokinetics*
D002792:Cholestyramine Resin; D010672:Phenytoin